Balancing efficacy and toxicity of a fibroblast activation protein dependent tetravalent CD40 agonist antibody for cancer therapy

被引：1
|
作者：
Chen, Simeng
Lin, Yuan
Zhou, Xiaoru
Sun, Xing
Yang, Changyong
Liao, Cheng
机构：
来源：
CANCER RESEARCH | 2024年 / 84卷 / 06期
关键词：
D O I：
10.1158/1538-7445.AM2024-2366
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2366
引用
收藏
页数：2
相关论文
共 50 条
  • [31] Clinical activity and immune modulation in cancer patients treated with CP-870,893, a novel CD40 agonist monoclonal antibody.
    Vonderheide, R. H.
    Flaherty, K. T.
    Khalil, M.
    Stumacher, M. S.
    Bajor, D. L.
    Gallagher, M.
    Sullivan, P.
    Mahaney, J. J.
    O'Dwyer, P. J.
    Huhn, R. D.
    Antonia, S. J.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 101S - 101S
  • [32] Local Activation of CD8 T Cells and Systemic Tumor Eradication without Toxicity via Slow Release and Local Delivery of Agonistic CD40 Antibody
    Fransen, Marieke F.
    Sluijter, Marjolein
    Morreau, Hans
    Arens, Ramon
    Melief, Cornelis J. M.
    CLINICAL CANCER RESEARCH, 2011, 17 (08) : 2270 - 2280
  • [33] Immune Activation and a 9-Year Ongoing Complete Remission Following CD40 Antibody Therapy and Metastasectomy in a Patient with Metastatic Melanoma
    Bajor, David L.
    Xu, Xiaowei
    Torigian, Drew A.
    Mick, Rosemarie
    Garcia, Laura R.
    Richman, Lee P.
    Desmarais, Cindy
    Nathanson, Katherine L.
    Schuchter, Lynn M.
    Kalos, Michael
    Vonderheide, Robert H.
    CANCER IMMUNOLOGY RESEARCH, 2014, 2 (11) : 1051 - 1058
  • [34] CD40 Agonist Restores the Antitumor Efficacy of Anti-PD1 Therapy in Muscle-Invasive Bladder Cancer in an IFN I/II-Mediated Manner
    Leblond, Marine M.
    Tille, Laure
    Nassiri, Sina
    Gilfillan, Connie B.
    Imbratta, Claire
    Schmittnaegel, Martina
    Ries, Carola H.
    Speiser, Daniel E.
    Verdeil, Gregory
    CANCER IMMUNOLOGY RESEARCH, 2020, 8 (09) : 1180 - 1192
  • [35] Intratumoral interleukin-2/agonist CD40 antibody drives CD4+-independent resolution of treated-tumors and CD4+-dependent systemic and memory responses
    Connie Jackaman
    Delia J. Nelson
    Cancer Immunology, Immunotherapy, 2012, 61 : 549 - 560
  • [36] Intratumoral interleukin-2/agonist CD40 antibody drives CD4+-independent resolution of treated-tumors and CD4+-dependent systemic and memory responses
    Jackaman, Connie
    Nelson, Delia J.
    CANCER IMMUNOLOGY IMMUNOTHERAPY, 2012, 61 (04) : 549 - 560
  • [37] STING and TLR-independent activation of T-cell responses against pancreatic cancer using agonistic CD40 antibody
    Byrne, Katelyn T.
    Morrison, Alexander H.
    Vonderheide, Robert H.
    CANCER RESEARCH, 2019, 79 (24)
  • [38] Activation of human B cells by the agonist CD40 antibody CP-870,893 and augmentation with simultaneous toll-like receptor 9 stimulation
    Erica L Carpenter
    Rosemarie Mick
    Jens Rüter
    Robert H Vonderheide
    Journal of Translational Medicine, 7
  • [39] Activation of human B cells by the agonist CD40 antibody CP-870,893 and augmentation with simultaneous toll-like receptor 9 stimulation
    Carpenter, Erica L.
    Mick, Rosemarie
    Rueter, Jens
    Vonderheide, Robert H.
    JOURNAL OF TRANSLATIONAL MEDICINE, 2009, 7 : 93
  • [40] Nab-paclitaxel and agonist CD40 mAb combination therapy induces tumor-associated macrophage polarization switching in pancreatic cancer
    Collis, Jane E.
    Siolas, Despina
    Maitra, Anirban
    Bar-Sagi, Dafna
    CANCER RESEARCH, 2015, 75
12345